Delayed 5-day change 1st Jan Change
- USD -.--% Intraday chart for Vaccinogen Inc -.--% -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
-1.26%-7.81%+156.15%+320.43% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average -0.53%+1.65%+35.97%+207.33% 30.54B
Weighted average by Cap. -0.47%+1.44%+35.38%+147.72%
Logo Vaccinogen Inc
Vaccinogen, Inc. is a biotechnology company. The Company is the developer of OncoVAX. OncoVAX is an active specific immunotherapy (ASI) that uses the patient's own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. OncoVAX is a patient specific immunotherapy for stage II colon cancer and its technology may have application in other tumor types, such as melanoma and renal cell carcinoma. The OncoVAX patient-specific vaccine consists of sterile, metabolically active, irradiated and non-tumorigenic autologous cancer cells, with or without fresh frozen Bacillus Calmette-Guerin (BCG) bacteria as an adjuvant. The Company has completed a Phase IIIa study of OncoVAX.
Employees
-
  1. Stock Market
  2. Stocks
  3. VGEN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!